{"status": "OK", "response": {"docs": [{"type_of_material": "Op-Ed", "blog": [], "news_desk": "OpEd", "lead_paragraph": "When a drug works, patients and insurance companies should pay the full price of the drug. When it doesn\u2019t, they should pay nothing.", "headline": {"seo": "Pay Only for Drugs That Help You", "main": "Pay Only for Drugs That Help You", "kicker": "Op-Ed Contributor", "print_headline": "Pay Only for Drugs That Help You", "content_kicker": "Op-Ed Contributor"}, "abstract": "Op-Ed article by Kadmon Corporation founder Samuel D Waksal proposes a system in which health care providers and patients would only pay for drugs if they are effective; holds method would cut costs and create incentives for drug developers; points out a pay-for-response model would also fuel scientific innovation.", "print_page": "27", "word_count": "825", "_id": "515b6b0ffdc59278db009e83", "snippet": "When a drug works, patients and insurance companies should pay the full price of the drug. When it doesn\u2019t, they should pay nothing.", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://www.nytimes.com/2012/03/07/opinion/pay-only-for-drugs-that-help-you.html", "multimedia": [], "subsection_name": null, "keywords": [{"value": "Drugs (Pharmaceuticals)", "is_major": "Y", "rank": "1", "name": "subject"}, {"value": "Health Insurance and Managed Care", "is_major": "Y", "rank": "2", "name": "subject"}, {"value": "Genetics and Heredity", "is_major": "N", "rank": "3", "name": "subject"}, {"value": "Biotechnology", "is_major": "N", "rank": "4", "name": "subject"}, {"value": "Prices (Fares, Fees and Rates)", "is_major": "N", "rank": "5", "name": "subject"}, {"value": "Cancer", "is_major": "N", "rank": "6", "name": "subject"}, {"value": "Reform and Reorganization", "is_major": "N", "rank": "7", "name": "subject"}], "byline": {"contributor": "", "person": [{"organization": "", "role": "reported", "rank": 1, "firstname": "Samuel"}], "original": "By SAMUEL D. WAKSAL"}, "document_type": "article", "pub_date": "2012-03-07T00:00:00Z", "section_name": "Opinion"}, {"type_of_material": "News", "blog": [], "news_desk": "Business", "lead_paragraph": "India\u2019s mass production of generic versions of drugs patented elsewhere helps poor people with treatment that would otherwise be too costly, but drug companies say the knockoffs stifle innovation.", "headline": {"main": "India\u2019s Supreme Court to Hear Dispute on Drug Patents", "print_headline": "Patent v. Patient"}, "abstract": "India\u2019s mass production of generic versions of drugs protected by global patents helps poor people with treatments that would otherwise be too costly, but drug companies say the knockoffs stifle innovation; case involving Novartis's cancer drug Gleevec before the Indian Supreme court represents a high-stakes showdown between defenders of intellectual property rights and Indian drug companies and international aid groups that warn that ruling in favor of Novartis could have lasting effects on the global supply chain of inexpensive drugs.", "print_page": "1", "word_count": "1455", "_id": "515b6b30fdc59278db009ea5", "snippet": "India\u2019s mass production of generic versions of drugs patented elsewhere helps poor people with treatment that would otherwise be too costly, but drug companies say the knockoffs stifle innovation.", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://www.nytimes.com/2012/03/07/business/global/indias-supreme-court-to-hear-long-simmering-dispute-on-drug-patents.html", "multimedia": [{"subtype": "xlarge", "url": "images/2012/03/07/business/global/07generics-span/07generics-span-articleLarge.jpg", "height": 350, "width": 600, "legacy": {"xlargewidth": "600", "xlarge": "images/2012/03/07/business/global/07generics-span/07generics-span-articleLarge.jpg", "xlargeheight": "350"}, "type": "image"}, {"subtype": "thumbnail", "url": "images/2012/03/07/business/global/07generics-span/07generics-span-thumbStandard-v2.jpg", "height": 75, "width": 75, "legacy": {"thumbnailheight": "75", "thumbnail": "images/2012/03/07/business/global/07generics-span/07generics-span-thumbStandard-v2.jpg", "thumbnailwidth": "75"}, "type": "image"}], "subsection_name": "Global Business", "keywords": [{"value": "India", "is_major": "Y", "rank": "1", "name": "glocations"}, {"value": "Drugs (Pharmaceuticals)", "is_major": "Y", "rank": "2", "name": "subject"}, {"value": "Generic Brands and Products", "is_major": "Y", "rank": "3", "name": "subject"}, {"value": "Inventions and Patents", "is_major": "N", "rank": "4", "name": "subject"}, {"value": "Suits and Litigation", "is_major": "N", "rank": "5", "name": "subject"}, {"value": "International Trade and World Market", "is_major": "N", "rank": "6", "name": "subject"}, {"value": "Novartis AG", "is_major": "Y", "rank": "7", "name": "organizations"}], "byline": {"contributor": "Vikas Bajaj reported from Mumbai, India, and Andrew Pollack from Los Angeles.", "person": [{"organization": "", "role": "reported", "rank": 1, "firstname": "Vikas", "lastname": "BAJAJ"}, {"organization": "", "role": "reported", "rank": 2, "firstname": "Andrew", "lastname": "POLLACK"}], "original": "By VIKAS BAJAJ and ANDREW POLLACK"}, "document_type": "article", "pub_date": "2012-03-07T00:00:00Z", "section_name": "Business Day"}, {"type_of_material": "Letter", "blog": [], "news_desk": "Letters", "lead_paragraph": "Readers respond to an Op-Ed article, \u201cIf You Feel O.K., Maybe You Are O.K.\u201d", "headline": {"main": "Too Many Medical Tests, Too Little Care?", "kicker": "Letters", "print_headline": "Too Many Medical Tests, Too Little Care?", "content_kicker": "Letters"}, "abstract": null, "print_page": "18", "word_count": "672", "_id": "53f435d179881034aaf5af0d", "snippet": "Readers respond to an Op-Ed article, \u201cIf You Feel O.K., Maybe You Are O.K.\u201d", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://www.nytimes.com/2012/03/03/opinion/too-many-medical-tests-too-little-care.html", "multimedia": [{"subtype": "wide", "url": "images/2012/03/03/opinion/03LETTERS/03LETTERS-thumbWide.jpg", "height": 126, "width": 190, "legacy": {"wide": "images/2012/03/03/opinion/03LETTERS/03LETTERS-thumbWide.jpg", "wideheight": "126", "widewidth": "190"}, "type": "image"}, {"subtype": "thumbnail", "url": "images/2012/03/03/opinion/03LETTERS/03LETTERS-thumbStandard.jpg", "height": 75, "width": 75, "legacy": {"thumbnailheight": "75", "thumbnail": "images/2012/03/03/opinion/03LETTERS/03LETTERS-thumbStandard.jpg", "thumbnailwidth": "75"}, "type": "image"}], "subsection_name": null, "keywords": [{"value": "Preventive Medicine", "is_major": "N", "rank": "1", "name": "subject"}, {"value": "Tests (Medical)", "is_major": "N", "rank": "2", "name": "subject"}, {"value": "Medicine and Health", "is_major": "N", "rank": "3", "name": "subject"}], "byline": [], "document_type": "article", "pub_date": "2012-03-03T00:00:00Z", "section_name": "Opinion"}], "meta": {"hits": 3, "offset": 0, "time": 48}}, "copyright": "Copyright (c) 2013 The New York Times Company.  All Rights Reserved."}